EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- ACCOLATE
- Benlysta 120 mg
- Protopic 0.1% ointment
- Aminophylline injection BP 500 mg/2 ml
- Gastrocote Liquid
- Equasym XL 10 mg, 20 mg or 30 mg Capsules
- Tazocin 2g/0.25g and 4g/0.5g Powder for Solution for Injection or Infusion
- Imodium Plus Caplets GSL
- Ilaris 150mg powder for solution for injection
- Voltarol 25mg, 50mg Rapid Tablets
- E45 Itch Relief Cream
- Lescol XL 80 mg Prolonged Release Tablets
- Onbrez Breezhaler 300 microgram inhalation powder, hard capsules
- Heparin calcium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion
- Kamillosan Ointment
- Hyoscine Hydrobromide 400 micrograms/ml Solution for Injection
- Abilify Tablets, Orodispersible Tablets, Oral Solution (Otsuka & Bristol-Myers Squibb)
- Anugesic HC Cream
- Arimidex 1mg Film-Coated Tablet
- Avodart 0.5mg soft capsules
- Gabapentin 100 mg Capsules
- Dovonex Ointment
- Premique Low Dose 0.3mg/1.5mg Modified Release Tablets
- Premique 0.625mg/5mg Coated Tablets
- Innohep 20,000 IU/ml and Innohep syringe 20,000 IU/ml
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Accupro Tablets 5mg, 10mg, 20mg & 40mg
- Acular
- Betaferon
- Cimzia 200 mg solution for injection
- Olanzapine 2.5mg Film-coated Tablets
- Pentasa Slow Release Tablets 1g
- COZAAR 2.5 mg/ml powder and solvent for oral suspension
- Daktarin Gold 2% Cream
- Edronax 4mg Tablets
- COZAAR 12.5 mg, 25 mg, 50 mg and 100 mg Film-Coated Tablets
- Tobi 300 mg/5 ml Nebuliser Solution
- Elocon Cream
- Famciclovir 125 mg Tablets
- Famciclovir 250mg Tablets
Benign Prostatic Hyperplasia (BPH)
Please note- The EPG Benign Prostatic Hyperplasia (BPH) Knowledge Centre is for Doctors and other Healthcare Professionals. Enter the Benign Prostatic Hyperplasia (BPH) Knowledge Centre
Benign prostatic hyperplasia is a progressive disease defined histologically and characterized by stromal and epithelial cell hyperplasia beginning in the periurethral zone of the prostate.1,2 The chief complaint of the patient with BPH is usually bothersome LUTS typified by urinary frequency, urgency, nocturia, decreased and intermittent force of stream and the sensation of incomplete bladder emptying.
BPH is often associated with enlargement of the prostate (BPE). However the relationship between BPH, LUTS (Lower Urinary Tract Symptoms) and BPE is complex and not all patients with BPH will have LUTS or BPE and also (BPE) may exist in the absence of LUTS.
BPH is one of the most common conditions affecting older men and can cause major disruption in everyday life (Marks et al 2006).
The presence of Lower Urinary Tract Symptoms (LUTS) although not specific or exclusive of BPH are characteristic of this disease.
The management of BPH should focus on the long-term improvement of patients' symptoms, improving quality of life, and relieving or preventing the development of serious secondary conditions. Options range from no active treatment (termed 'watchful waiting'), through drug therapy, to surgical intervention.
Guidelines for the management of BPH are also available
Enter the Benign Prostatic Hyperplasia (BPH) Knowledge Centre
What’s in the Benign Prostatic Hyperplasia (BPH) Knowledge Centre?
- Understanding BPH: Definition
- The Prostate
- BPH Definition
- BPH Clinical Features
- Progression of BPH
- Clinical Features
- Prevalence and Burden
- Management of BPH: Watchful Waiting
- Phytotherapy
- Pharmacotherapy
- Surgical Interventions
- Other Minimally Invasive Treatments: including Thermotherapy
- Dutasteride: Product Characteristics
- Efficacy Data
- Safety and Tolerability Data
- Effect on PSA
- Additional Resources: BPH Guidelines
- References
- 5a-reductase
- a-blocker
- acute urinary retention (AUR)
- anabolic steroid
- androgen
- anti-androgen
- anticholinergic drugs
- apoptosis benign prostatic hyperplasia (BPH)
- cholestyramine
- clastogen
- cytochrome P450
- diazepam
- digital rectal examination (DRE)
- digoxin
- dihydrotestosterone (DHT)
- diltiazem
- doxazosin
- dribbling/terminal dribbling
- Dysuria
- epididymis
- finasteride (Proscar)
- frequency
- gynaecomastia
- haematuria
- haematospermia
- hesitancy
- hydronephrosis
- impotence
- incontinence
- indinavir
- Incomplete voiding/emptying
- intermittency
- isoenzyme
- itraconozole
- ketoconazole
- libido
- malaise
- mutagen
- nefazodon
- neoadjuvant therapy
- nocturia
- oestrogens
- phenytoin
- phytotherapy
- prostate-specific antigen (PSA)
- prostatectomy
- Qmax
- retrograde ejaculation
- ritonavir
- semen
- seminal vesicles
- spermatogenesis
- tamsulosin
- terazosin
- testosterone
- urgency
- urosepsis
- verapamil
- volume of distribution
- warfarin
- watchful waiting
- weak urinary stream
References
1. Lee, C., Cockett, A., Cussenot, K., Griffiths, K., Isaacs, W., and Schalken. “Regulation of Prostate Growth”. In: Proceedings of the Fifth International Consultation on BenignProstatic Hyperplasia. Edited by C. Chatelain, L. Denis, K.T. Foo, S. Khoury, and J. McConnell. United Kingdom: Health Publications Ltd., chapt. 3, 79-106, 2001.
2. McNeal, J. E. Origin and evolution of benign prostatic enlargement. Invest Urol, 15: 340, 1978.
- HYTRIN
Orally administered Hytrin BPH is indicated as a therapy for the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH). Terazosin is a selective post synaptic alpha-1-adrenoreceptor antagonist. Antagonism of alpha-1-receptors on prostatic and urethral smooth ... - CARDURA XL Tablets
... benign prostatic hyperplasia (BPH). Cardura XL may be used in BPH patients who are either hypertensive or normotensive. While the blood pressure changes in normotensive patients with BPH are not usually clinically significant, patients with hypertension and BPH have had both conditions effectively ... - Avodart 0.5mg soft capsules
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH ... - PROSCAR (BPH)
... for the treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to: − cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH − reduce the incidence of acute urinary retention and the need for ... - CARDURA Tablets
... or an angiotensin-converting enzyme inhibitor. Benign prostatic hyperplasia:Cardura is indicated for the treatment of urinary outflow obstruction and symptoms associated with benign prostatic hyperplasia (BPH). Cardura may be used in BPH patients who are either hypertensive or normotensive ... - Pinexel PR 400 micrograms Prolonged-Release Hard Capsules
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH ...
